AT2 Agonist C21 CAS: 477775-14-7

CAS NO: 477775-14-7
AT2 Agonist C21
Chemical Name: M 24
Molecular Formula: C23H29N3O4S2
Formula Weight: 475.62
CAS No.: 477775-14-7
Description Review
Description

AT2 Agonist C21 is a potent and highly selective agonist of the angiotensin II type 2 receptor. This product has gained significant interest in the scientific community due to its potential therapeutic properties, including its ability to reduce inflammation, promote tissue repair, and protect against cardiovascular disease.

Chemical name:

The chemical name of AT2 Agonist C21 is N-(1-(4-(2-((2S)-2-(3-(benzyloxy)propyl)-1H-indol-5-yl)ethylamino)ethyl)indol-7-carbonyl)-L-valine.

Molecular formula:

The molecular formula of AT2 Agonist C21 is C43H54N6O5.

Formula weight:

The formula weight of AT2 Agonist C21 is 766.93 g/mol.

CAS No:

The CAS number for AT2 Agonist C21 is 477775-14-7.

Top ten keywords from Google and Synonyms:

  1. AT2 Agonist C21
  2. Angiotensin II type 2 receptor
  3. CAS number 477775-14-7
  4. Tissue repair
  5. Cardiovascular disease
  6. Inflammation
  7. Therapeutic properties
  8. Selective agonist
  9. AT2 receptor
  10. Valine

Synonyms:

  1. N-(1-(4-(2-((2S)-2-(3-(benzyloxy)propyl)-1H-indol-5-yl)ethylamino)ethyl)indol-7-carbonyl)-L-valine
  2. C21
  3. Ang-(1-7) analogue
  4. AngII antagonist
  5. AT2 selective ligand

Health benefits of this product:

AT2 Agonist C21 has been found to have various health benefits due to its ability to activate the angiotensin II type 2 receptor. This includes its potential to reduce inflammation, promote tissue repair, and protect against cardiovascular disease. It may also have neuroprotective effects and could potentially be used to treat conditions such as Alzheimer's disease.

Potential effects:

AT2 Agonist C21 activates the angiotensin II type 2 receptor. This leads to various effects on the body, including vasodilation, anti-inflammatory effects, and stimulation of tissue repair. It may also have neuroprotective effects and act as an antioxidant. Further research is needed to fully understand the mechanisms of action and potential uses of this product.

Product mechanism:

The exact mechanism of action of AT2 Agonist C21 is not fully understood. However, it is believed to work by activating the angiotensin II type 2 receptor, which leads to vasodilation, reduced inflammation, and increased tissue repair. It may also have neuroprotective effects and act as an antioxidant.

Safety:

AT2 Agonist C21 is still being studied for its safety profile. While early studies have shown promising results, more research is needed to fully evaluate its safety and potential side effects.

Side effects:

There are currently no reports of significant side effects associated with the use of AT2 Agonist C21. However, as with any medication, there is always a risk of adverse effects. It is important to consult with a healthcare professional before using this product.

Dosing information:

The recommended dosage of AT2 Agonist C21 varies depending on the intended use and application. It is important to follow dosing instructions carefully and consult with a healthcare professional before use.

Conclusion:

AT2 Agonist C21 is a promising compound that has shown potential therapeutic properties, including its ability to reduce inflammation, promote tissue repair, and protect against cardiovascular disease. While more research is needed to fully understand its mechanisms of action and potential uses, early studies have shown promising results. As with any medication, it is important to follow dosing instructions carefully and consult with a healthcare professional before use

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code